Summary
We analyzed the results of clinical studies on the therapeutic efficacy of hormone monotherapy with tamoxifen, medroxyprogesterone acetate, and aminoglutethimide in metastatic breast cancer, which were published between 1971 and 1986 and involved altogether 7000 patients. The overall response rates in patients treated with these hormonal single agents at various dose levels ranged from 31%–42%. When only estrogen receptor-positive patients were considered, the response rates lay between 41% and 54% in groups which were treated with the antiestrogenic agents tamoxifen or aminoglutethimide. The duration of remission was 12 months for tamoxifen- and aminoglutethimide-treated women, whereas medroxy-progesterone acetate effected remissions lasting from 6–16 months. The overall mean survival from start of therapy in tamoxifen- and aminoglutethimide-treated groups was 20 months, whereas information concerning this therapeutic parameter was available only in a minority of medroxyprogesterone acetate-treated groups. With respect to the response by site of metastatic lesions, all three agents caused a significantly higher degree of remissions in the soft tissue as compared to visceral disease.
Similar content being viewed by others
Abbreviations
- AG:
-
Aminoglutethimide
- MPA:
-
Medroxyprogesterone acetate
- TAM:
-
Tamoxifen
References
Asbury R, Bakemeier R, Fölsch E, McCuine C, Savlov E, Bennet J (1981) Treatment of metastatic breast cancer with aminoglutethimide. Cancer 47:1954–1958
Bastert G, Michel R (1983) Hochdosierte Gestagentherapie mit Medroxyprogesteronacetat beim metastasierenden Mammakarzinom. Med Welt 34:378–382
Bastert G, Michel R, Schmidt-Matthiesen H (1984) Medroxyprogesteronacetat in hoher Dosierung zur Therapie metastasierender Mammakarzinome. In: Schmidt C, Schmidt-Matthiesen H (eds) Medroxyprogesteronacetat in der Onkologie. Schattauer, Stuttgart New York, pp 9–23
Becher R, Miller A, Höffken K, Firusian N, Gerhold U, Schmidt C (1984) Hochdosierte Behandlung mit Medroxyprogesteronacetat beim metastasierenden Mammakarzinom: eine Phase-II Studie. In: Schmidt CG, Schmidt-Matthiesen H (eds) Medroxyprogesteronacetat (MPA) in der Onkologie. Schattauer, Stuttgart New York, pp 39–52
Beex L, Pieters G, Smals A, Koenders A, Benraad T, Kloppenborg P (1981) Tamoxifen versus ethinyl estradiol in the treatment of postmenopausal women with advanced breast cancer. Cancer Treat Rep 65:179–185
Beretta G, Tabiadon D, Tedeschi L, Luporini G (1982) Hormonotherapy of advanced breast carcinoma: comparative evaluation of tamoxifen citrate versus medroxyprogesterone acetate. In: Iacobelli S, Lippmann M, Robustelli Della Cuna G (1982) The role of tamoxifen in breast cancer. Raven Press, New York, pp 113–120
Castiglione M, Cavalli F (1980) Ergebnisse einer Pilotstudie mit hochdosiertem Medroxyprogesteronacetat in der Behandlung des metastasierenden Mammakarzinoms. Schweiz Med Wochenschr 110:1073–1076
Cavalli F, Goldhirsch A, Jungi F, Martz G, Alberto P (1983) Low- versus high-dose medroxyprogesterone acetate in the treatment of advanced breast cancer. In: Campio L, Robustelli della Cuna G, Taylor RW (eds) Role of medroxyprogesterone in endocrine-related tumors. Raven Press, New York, vol II, pp 69–75
Cavalli F, Goldhirsch A, Jungi F, Martz G, Mermillod B, Alberto P (1984) Randomized trial of low- versus high-dose medroxyprogesterone acetate in the induction treatment of postmenopausal patients with advanced breast cancer. J Clin Oncol 2:414–419
Cole M, Jones C, Todd H (1971) A new antioestrogenic agent in late breast cancer: an early clinical appraisal of ICI46474. Br J Cancer 25:270–275
Cole M, Jones C, Todd H (1972) The treatment of advanced carcinoma of the breast with the antiestrogenic agent tamoxifen (ICI 46474) — a series of 96 patients. Advances in antimicrobial and antineoplastic chemotherapy (7th Int Congr Chemotherapy, Prague 1971). Urban-Schwarzenberg, München Berlin Wien, pp 529–531
Cortes-Funes H, Madrigal P, Perez-Mangas G, Mendiola C (1983) Medroxyprogesterone acetate at two different high doses for the treatment of advanced breast cancer. In: Campio L, Robustelli Della Cuna G, Taylor RW (eds) Role of medroxyprogesterone in endocrine-related tumors. Raven Press, New York, vol II, pp 77–82
De Lena M, Volonterio A (1982) Efficacy of tamoxifen in metastatic breast cancer — the experience of the national cancer institute of Milan. In: Iacobelli S, Lippmann M, Robustelli Della Cuna G (eds) The role of tamoxifen in breast cancer. Raven Press, New York, pp 65–72
DeLena M, Brambilla C, Valagussa P, Bonadonna G (1979) High-dose medroxyprogesterone acetate in breast cancer resistant to endocrine and cytotoxic therapy. Cancer Chemother Pharmacol 2:175–180
Fabian C, Sternson L, El-Serafi M, Cain L, Hearne E (1981) Clinical pharmacology of tamoxifen in patients with breast cancer: correlation with clinical data. Cancer 48:876–882
Goldhirsch A, Cavalli F, Joss R, Ryssel H, Leuenberger U, Brunner K (1982) An evaluation of tamoxifen dose escalation in advanced breast cancer. Am J Clin Oncol 5:501–503
Harris A, Dowsett M, Smith I, Jeffcoate S (1983) Aminoglutethimide induced hormone suppression and response to therapy in advanced postmenopausal breast cancer. Br J Cancer 48:585–594
Harris A, Powles T, Smith I, Coombes R, Ford H, Gazet J, Harmer C, Morgan M, White H, Parsons C, McKinna J (1983) Aminoglutethimide for the treatment of advanced postmenopausal breast cancer. Eur J Cancer Clin Oncol 19:11–17
Harris A, Dowsett M, Smith I, Jeffcoate S (1984) Hydrocortisone alone vs hydrocortisone plus aminoglutethimide: a comparison of the endocrine effects in postmenopausal breast cancer. Eur J Cancer Clin Oncol 20:463–469
Harvey H, Santen R, Osterman J, Samojlik E, White D, Lipton A (1979) A comparative trial of transsphenoidal hypophysectomy and estrogen suppression with aminoglutethimide in advanced breast cancer. Cancer 43:2207–2214
Harvey H, Lipton A, White D, Santen R, Boucher A, Shafik A, Dixon R (1982) Cross-over comparison of tamoxifen and aminoglutethimide in advanced breast cancer. Cancer Res 42 (Suppl): 3451s-3453s
Harvey H, Lipton A, Santen R (1986) Clinical studies with aminoglutethimide in advanced breast carcinoma. Acta Clin Belg 41 (Suppl II):29–40
Heuson J (1976) Current overview of EORTC clinical trials with tamoxifen. Cancer Treat Rep 60:1463–1466
Hoogstraaten B, Fletcher W, Gad-el-Mawla N, Maloney T, Altman S, Vaughn C, Foulkes M (1982) Tamoxifen and oophorectomy in the treatment of recurrent breast cancer. Cancer Res 42:4788–4791
Horsley S, Newsome H, Brown P, Neifeld J, Terz J, Lawrence W (1982) Medical adrenalectomy in patients with advanced breast cancer. Cancer 49:1145–1149
Ingle J, Ahmann D, Green S, Edmonson J, Bisel H, Kvols L, Nichols W, Creagan E, Hahn R, Rubin J, Frytak S (1981) Randomized clinical trial of diethylstilbestrol versus tamoxifen in postmenopausal women with advanced breast cancer. N Engl J Med 304:16–21
Ingle J, Green S, Ahmann D, Edmonson J, Nichols W, Frytak S, Rubin J (1982) Progress report on two clinical trials in women with advanced breast cancer. Trial I: tamoxifen versus tamoxifen plus aminoglutethimide; trial II: aminoglutethimide in patients with prior tamoxifen exposure. Cancer Res 42 (Suppl):3461s-3467s
Ingle J, Green S, Ahmann D, Long H, Edmonson J, Rubin J, Chang M, Creagan E (1986) Randomized trial of tamoxifen alone or combined with aminoglutethimide and hydrocortisone in women with metastatic breast cancer. J Clin Oncol 4:958–964
Kiang D, Kennedy B (1977) Tamoxifen (antiestrogen) therapy in advanced breast cancer. Ann Int Med 87:687–690
Kühböck J, Ludwig H, Aiginger P, Linkesch W, Pötzi P (1982) Die Behandlung des metastasierenden Mammakarzinoms mit Aminoglutethimid. Acta Med Austriaca 9:221–226
Lawrence B, Lipton A, Harvey H, Santen R, Wells S, Cox C, White D, Smart E (1980) Influence of estrogen receptor status on response of metastatic breast cancer to aminoglutethimide therapy. Cancer 45:786–791
Legha S, Buzdar A, Hortobagyi G, Wiseman C, Benjamin R, Blumenschein G (1979) Tamoxifen: use in treatment of metastatic breast cancer refractory to combination chemotherapy. JAMA 242:49–52
Lerner H, Band P, Israel L, Leung B (1976) Phase II study of tamoxifen: report of 74 patients with stage IV breast cancer. Cancer Treat Rep 60:1431–1435
Lipton A, Harvey H, Santen R, Boucher A, White D, Bernath A, Dixon R, Richards G, Shafik A (1982) A randomized trial of aminoglutethimide versus tamoxifen in metastatic breast cancer. Cancer 50:2265–2268
Lipton A, Harvey H, Santen R, Boucher A, White D, Bernath A, Dixon R, Richards G, Shafik A (1982) Randomized trial of aminoglutethimide versus tamoxifen in metastatic breast cancer. Cancer Res 42 (Suppl):3434s-3436s
Manni A, Pearson O (1980) Antiestrogen-induced remissions in premenopausal women with stage IV breast cancer: effects on ovarian function. Cancer Treat Rep 64:779–785
Manni A, Trujillo J, Marshall J, Pearson O (1976) Antiestrogen-induced remissions in stage IV breast cancer. Cancer Treat Rep 60:1445–1450
Manni A, Trujillo J, Marshall J, Brodkey J, Pearson O (1979) Antihormone treatment of stage IV breast cancer. Cancer 43:444–450
Matelski H, Greene R, Huberman M, Lokich J, Zipoli T (1985) Randomized trial of estrogen vs tamoxifen therapy for advanced breast cancer. Am J Clin Oncol 8:128–133
Mattsson W (1978) High dose medroxyprogesterone-acetate treatment in advanced mammary carcinoma. Acta Radiol Oncol 17:387–400
Mattsson W (1980) A phase III trial of treatment with tamoxifen versus treatment with high dose medroxyprogesterone-acetate in advanced postmenopausal breast cancer. In: Iacobelli S, Di Marco A (eds) Role of medroxyprogesterone in endocrine-related tumors. Raven Press, New York, pp 65–71
Milsted R, Habeshaw T, Kaye S, Sangster G, Macbeth F, Campbell-Ferguson J, Smith D, Calman K (1985) A randomised trial of tamoxifen versus tamoxifen with aminoglutethimide in postmenopausal women with advanced breast cancer. Cancer Chemother Pharmacol 14:272–273
Morgan L, Schein P, Woolley P, Hoth D, Macdonald J, Lippmann M, Posey L, Beazley R (1976) Therapeutic use of tamoxifen in advanced breast cancer: correlation with biochemical parameters. Cancer Treat Rep 60:1437–1443
Mouridsen H, Ellemann K, Mattsson W, Palshof T, Daehnfeldt J, Rose C (1979) Therapeutic effect of tamoxifen versus tamoxifen combined with medroxyprogesterone acetate in advanced breast cancer in postmenopausal women. Cancer Treat Rep 63:171–175
Mouridsen H, Salimtschik M, Dombernowsky P, Gelshoj K, Palshof T, Rorth M, Daenfeldt J, Rose C (1980) Therapeutic effect of tamoxifen versus combined tamoxifen and diethylstilboestrol in advanced breast cancer in postmenopausal women. Eur J Cancer 16 (Suppl 1):107–110
Murray R, Pitt P (1981) Medical adrenalectomy in patients with advanced breast cancer resistant to anti-oestrogen treatment. Breast Cancer Res Treat 1:91–95
Murray R, Pitt P (1982) Aminoglutethimide in tamoxifen-resistant patients: the Melbourne experience. Cancer Res 42 (Suppl):3437s-3441s
Murray R, Pitt P, Jerums G (1981) Medical adrenalectomy with aminoglutethimide in the management of advanced breast cancer. Med J Aust 1:179–181
Newsome H, Brown P, Terz J, Lawrence W (1977) Medical and surgical adrenalectomy in patients with advanced breast carcinoma. Cancer 39:542–546
Pannuti F (1979) Die hochdosierte Gestagenbehandlung in der Therapie des fortgeschrittenen Mammakarzinoms. Onkologie 2:54–60
Pannuti F, Martoni A, Lenaz G, Piana E, Nanni P (1978) A possible new approach to the treatment of metastatic breast cancer: massive doses of medroxyprogesterone acetate. Cancer Treat Rep 62:499–504
Pannuti F, Martoni A, Di Marco A, Piana E, Saccani F, Becchi G, Mattioli G, Barbanti F, Marra G, Persiani W, Cacciari L, Spagnolo F, Palenzona D, Rocchetta G (1979) Prospective, randomized clinical trial of two different high dosages of medroxyprogesterone acetate (MAP) in the treatment of metastatic breast cancer. Eur J Cancer 15:593–601
Pannuti F, Martoni A, Fruet F, Strocchi E, Di Marco A (1980) Hormone therapy in advanced breast cancer: high dose medroxyprogesterone acetate (MAP) vs tamoxifen (TMX). Preliminary results. Eur J Cancer 16 (Suppl 1):93s-98s
Pannuti F, Di Marco A, Martoni A, Fruet F, Strocchi E, Burroni P, Rossi A, Cricca A (1980) Medroxyprogesterone acetate in treatment of metastatic breast cancer: seven years of experience. In: Iacobelli S, Di Marco A (eds) Role of medroxyprogesterone in endocrine-related tumors. Raven Press, New York, pp 73–92
Pannuti F, Martoni A, Fruet F, Burroni P, Canova N, Hall S (1982) Oral high dose medroxyprogesterone acetate versus tamoxifen in postmenopausal patients with advanced breast cancer. In: Iacobelli S, Lippmann M, Robustelli Della Cuna G (eds) The role of tamoxifen in breast cancer. Raven Press, New York, pp 85–92
Pannuti F, Gentili M, Di Marco A, Martoni A, Giambiasi M, Battistoni R, Camaggi C, Burroni P, Strocchi E, Iafelice G, Piana E, Murari G (1983) The results of treatment with medroxyprogesterone acetate at high and very high doses in 237 metastatic breast cancer patients in postmenopause. In: Campio L, Robustelli Della Cuna, Taylor R (eds) Role of medroxyprogesterone in endocrine-related tumors. Raven press, New York, vol II, pp 95–103
Paridaens R, Van Haelen C, Heuson J (1980) Medical adrenalectomy with aminoglutethimide-cortisol in the treatment of metastatic breast carcinoma. Eur J Cancer 16 (Suppl 1):103s-106s
Petru E, Schmähl D (1986) On the relevance of “second-line” cytotoxic chemotherapy in patients with metastatic breast cancer resistant to standard combinations. Wien Klin Wochenschr 23:790–797
Petru E, Schmähl D (1987) Zur Bedeutung der Zusammensetzung verschiedener Kombinationsschemata bei der Chemotherapie des metastasierten Mammakarzinoms. Deutsch Med Wochenschr 112:270–275
Pouillart P, Jouve M, Palangie T, Garcia-Giralt E, Bretaudeau B, Magdelenat H, Asselain B (1984) Disseminated breast cancer: sequential administration of tamoxifen and medroxyprogesterone acetate, Results of a controlled trial. In: Pellegrini A (ed) Role of medroxyprogesterone in endocrine-related tumors. Raven Press, New York, vol 3, pp 141–155
Powels T, Gordon C, Coombes R (1982) Clinical trial of multiple endocrine therapy for metastatic and locally advanced breast cancer with tamoxifen-aminoglutethimide-danazol compared to tamoxifen used alone. Cancer Res 42 (Suppl):3458s-3460s
Powels T, Coombes R, Smith I (1984) Erfahrungen mit Aminoglutethimid in der Behandlung von Patientinnen mit metastasierendem Mammakarzinom. In: Nagel G, Schmitt-Matthiesen H, Drees N (eds) Aminoglutethimid: ein Antiöstrogen mit Aromatasehemmung. Zuckschwerdt, München, pp 35–40
Pritchard K, Meakin W, Myers R, Sutherland D, Mobbs B (1978) Tamoxifen and metastatic breast cancer. Ann Int Med 89:721–722
Pritchard K, Thomson D, Myers R, Sutherland D, Mobbs B, Meakin W (1980) Tamoxifen therapy in premenopausal patients with metastatic breast cancer. Cancer Treat Rep 64:787–796
Robustelli Della Cuna G, Calciati A, Strada M, Bumma C, Campio L (1978) High dose medroxyprogesterone acetate (MPA) treatment in metastatic carcinoma of the breast: a dose-response evaluation. Tumori 64:143–149
Rose K, Theilade K, Boesen E, Salimtschik M, Dombernowsky P, Brünner N, Kjaer M, Mouridsen H (1982) Treatment of advanced breast cancer with tamoxifen: evaluation of the dose-response relationship at two dose levels. Breast Cancer Res Treat 2:395–400
Ross M, Buzdar A, Blumenschein G (1982) Treatment of advanced breast cancer with megestrol acetate after therapy with tamoxifen. Cancer 49:413–417
Santen R, Lipton A, Kendall J (1974) Successful medical adrenalectomy with amino-glutethimide. JAMA 230:1661–1665
Santen R, Worgul T, Samojlik E, Interrante A, Boucher A, Lipton A, Harvey H, White D, Smart E, Cox C, Wells S (1981) A randomized trial comparing surgical adrenalectomy with aminoglutethimide plus hydrocortisone in women with advanced breast cancer. N Engl J Med 305:545–551
Santen R, Worgul T, Lipton A, Harvey H, Boucher A, Samojlik E, Wells S (1982) Aminoglutethimide as treatment of postmenopausal women with advanced breast carcinoma. Ann Int Med 96:94–101
Savaraj N, Troner M (1980) Aminoglutethimide in the management of metastatic breast cancer. Med Pediatr Oncol 8:251–263
Sawka C, Pritchard K, Paterson A, Sutherland D, Thomson D, Shelley W, Myers R, Mobbs B, Malkin A, Meakin W (1986) Role and mechanism of action of tamoxifen in premenopausal women with metastatic breast carcinoma. Cancer Res 46:3152–3156
Smith I, Fitzharris B, Mc Kinna J (1978) Aminoglutethimide in treatment of metastatic breast carcinoma. Lancet II 23:646–649
Smith I, Coombes R, Ford M, Gazet J, Harmer C, Jones M, Mc Kinna J, Powles T (1980) Aminoglutethimide in the management of advanced breast cancer. Eur J Cancer (Suppl 1) 16:99s-101s
Smith I, Harris A, Morgan M, Gazet J, Mc Kinna J (1982) Tamoxifen versus aminoglutethimide in the treatment of advanced breast carcinoma. Cancer Res 42 (Suppl):3430s-3433s
Stewart H, Forrest A, Gunn J, Hamilton T, Langlands A, McFayden I, Roberts M (1980) The tamoxifen trial — a double-blind comparison with stilboestrol in postmenopausal women with advanced breast cancer. Eur J Cancer 16 (Suppl 1):83–88
Stewart J, Minton M, Rubens R (1982) Trial of tamoxifen at a dose of 40 mg daily after disease progression during tamoxifen therapy at a dose of 20 mg daily. Cancer Treat Rep 66:1445–1446
Tanaka M, Abe K, Ohnami S, Adachi I, Yamaguchi K, Miyakawa S (1978) Tamoxifen in advanced breast cancer; response rate, effect on pituitary hormone reserve and binding affinity to estrogen receptor. Jap J Clin Oncol 8:141–148
Troner M (1982) Aminoglutethimide in the treatment of metastatic breast cancer. Cancer Res 42 (Suppl):3402s-3404s
Veronesi A, Frustaci S, Tirelli U, Galligioni E, Trovo M, Crivellari D, Magri M, Figoli F, Talamini R, Tumolo S, Grigoletto E (1982) Tamoxifen therapy in locally advanced, inoperable T3–T4 breast carcinoma in 53 postmenopausal women. In: Iacobelli S, Lippmann M, Robustelli Della Cuna G (eds) The role of tamoxifen in breast cancer. Raven Press, New York, pp 107–111
Viladiu P, Bosch F, Benito E, Alonso M (1977) Antiestrogen tamoxifen in the treatment of advanced breast cancer: a series of 31 patients. Cancer Treat Rep 61:899–900
Wada T, Koyama H, Terasawa T (1981) Effect of tamoxifen in premenopausal Japanese women with advanced breast cancer. Cancer Treat Rep 65:728–729
Wander H, Bloosey C, Köbberling J, Nagel G (1983) Hochdosiertes Medroxyprogesteronacetat beim metastasierenden Mammakarzinom: Beziehung zwischen Krankheitsverlauf und Hormonprofilen. Klin Wochenschr 61:553–560
Ward H (1973) Anti-oestrogen therapy for breast cancer: a trial of tamoxifen at two dose levels. Br Med J 1:13–14
Wells S, Santen R, Lipton A, Haagensen D, Ruby E, Harvey H, Dilley W (1978) Medical adrenalectomy with aminoglutethimide. Ann Surg 178:475–484
Westerberg H (1980) Tamoxifen and fluoxymesterone in advanced breast cancer: a controlled clinical trial. Cancer Treat Rep 64:117–121
Westerberg H, Nordenskjöld B, Schryver A, Notter G (1976) Anti-oestrogen therapy of advanced mammary carcinoma. Acta Radiol Ther Phys Biol 15:513–518
Wiggans R, Wooley P, Smythe T, Hoth D, Macdonald J, Green L, Schein P (1979) Phase-II trial of tamoxifen in advanced breast cancer. Cancer Chemother Pharmacol 3:45–48
Willis K, London D, Ward H, Butt W, Lynch S, Rudd B (1977) Recurrent breast cancer treated with the antiestrogen tamoxifen: correlation between hormonal changes and clinical course. Br Med J 1:425–428
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Petru, E., Schmähl, D. On the role of additive hormone monotherapy with tamoxifen, medroxyprogesterone acetate and aminoglutethimide, in advanced breast cancer. Klin Wochenschr 65, 959–966 (1987). https://doi.org/10.1007/BF01717830
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01717830